DOCSLIB.ORG

For Personal Use Only

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
For Personal Use Only CP_02.06_CATIE.Final 1/17/06 4:50 PM Page 48 Copyright® Dowden Health Media For personal use only For mass reproduction, content licensing and permissions contact Dowden Health Media. CP_02.06_CATIE.Final 1/17/06 4:51 PM Page 49 Current p SYCHIATRY In antipsychotics’ square-off, were there winners or losers? nvestigators faced a dilemma while designing the Clinical Antipsychotic Trials of Inter- I vention Effectiveness (CATIE). More than 200 enrollees with chronic schizophrenia had pre-exist- Henry A. Nasrallah, MD ing tardive dyskinesia (TD). Would it be ethical to Professor of psychiatry, neurology, and neuroscience give them the antipsychotic most likely to worsen Department of psychiatry their TD? Would exempting them from taking that University of Cincinnati College of Medicine Member, CATIE Study Investigators Group drug influence the trial’s outcome? This issue and others had to be resolved before the largest controlled study of “real world” schizo- phrenia could begin. Now that data are unfolding, Perphenazine was as effective groups with diverse agendas are debating CATIE’s as the atypical antipsychotics, methods and surprising results. This article des- but could the study’s design cribes how the trial’s design and findings could have swayed the outcome? transform public policy and clinical practice. EFFICACY VS EFFECTIVENESS The National Institute of Mental Health funded the prospective CATIE schizophrenia study to compare the effectiveness of atypical antipsy- ispot chotics versus each other and versus a first-gener- the ation (typical) antipsychotic. c/o Yeo All approved atypicals have shown similar effi- Brad cacy compared with placebo in short-term trials © VOL. 5, NO. 2 / FEBRUARY 2006 49 CP_02.06_CATIE.FinalREV 1/18/06 2:17 PM Page 50 CATIE Table 1 medications, or show evidence of Criteria for enrolling patients TD. Their schizophrenia ranged in the CATIE schizophrenia trial from minimal to severe.2,3 The 1,493 patients who complet- Inclusion criteria Ages 18 to 65 yrs ed the study (Table 2) were enrolled DSM-IV diagnosis of schizophrenia at 57 outpatient treatment settings. One site’s 33 patients were eliminat- Able to take oral medication ed from analysis because of doubts Able to give informed consent about the integrity of the data, leav- 4 Exclusion criteria Diagnosis of schizoaffective ing a total of 1,460 subjects. disorder, mental retardation, Medications. Before randomization, or other cognitive disorders 28% of enrollees were not receiving History of serious adverse reactions antipsychotics. The remainder were to one of the study medications receiving: • olanzapine (22%) Had only one schizophrenic episode • risperidone (19%) History of treatment resistance, • quetiapine (7%) defined as persistence of severe • ziprasidone (0%; approved symptoms despite adequate trials after the trial began) of one of the study antipsychotics • any combination of olanzap- or prior treatment with clozapine ine, risperidone, and quetia- Pregnant or breast feeding pine (7%) Serious and unstable medical • typical antipsychotics (16%). conditions Metabolic profile. These outpatients had a high rate of metabolic disor- ders: 42%—twice the rate in the gen- eral population—met criteria for (usually 6 weeks).1 The CATIE trial’s rationale is metabolic syndrome,5 putting them at high risk to that short-term efficacy studies required for FDA die of cardiovascular causes within 10 years.6 approval may not necessarily reflect the drugs’ effectiveness in long-term schizophrenia manage- ment. Effectiveness measures take into account efficacy as well as safety, tolerability, and unpre- What do you think? dictable patient behaviors in the real world. Go to the Instant Poll www.currentpsychiatry.com CATIE'S 'REAL WORLD' PATIENTS CATIE investigators enrolled a community sample Will the CATIE findings of chronic schizophrenia patients similar to those change the way you treat many psychiatrists see. Very liberal inclusion and patients with schizophrenia? exclusion criteria (Table 1) allowed enrollees to have a history of substance abuse, comorbid psy- chiatric or medical disorders, be receiving other continued on page 53 50 Current VOL. 5, NO. 2 / FEBRUARY 2006 p SYCHIATRY CP_02.06_CATIE.Final 1/17/06 4:51 PM Page 53 Current p SYCHIATRY continued from page 50 They had relatively poor physical Table 2 health self-ratings and increased CATIE’s 1,460 ‘real world’ somatic preoccupation.7 Most worri- schizophrenia patients at trial entry some, many were receiving no med- Mean age 40.6 ± 11.1 yrs ications for their metabolic disor- ders, including 45% of those with Mean age of first treatment 24.0 ± 8.9 yrs diabetes, 89% with hyperlipidemia, Mean duration of treatment 14.4 ± 10.7 yrs and 62% with hypertension.8 Substance abuse. At enrollment, 40% Gender 74% male of patients were abstinent from sub- Race 60% white, 35% black, 5% other stance use, 22% were using sub- Mean education 12.1 ± 2.3 years stances without abuse or depen- dence, and 37% had substance abuse Marital status 59% never married, or dependence. Compared with 29% previously married, nonusers, substance abusers tended 11% married to be male with more childhood Employment status 85% unemployed problems, higher positive symptoms Mean PANSS total score 75.7 ± 17.6 on the Positive and Negative Syndrome Scale (PANSS), and Mean CGI 4.0 ± 0.9 more likely to have had a recent ill- Psychiatric comorbidities 29% drug dependence/abuse ness exacerbation.9 28% depression Tardive dyskinesia. The 231 subjects 25% alcohol dependence/abuse who met criteria for probable TD10 14% anxiety disorder were older than the overall sample 5% obsessive-compulsive with more years of antipsychotic disorder treatment, especially with conven- Illness severity 4% severe, 20% marked, tional neuroleptics and anticholin- 47% moderate, 23% mild, ergics. Substance abuse was associ- 6% minimal ated with TD, as were severity of PANSS: Positive and Negative Syndrome Scale CGI: Clinician-rated Clinical Global Impressions severity score psychopathology, extrapyramidal Source: Reference 5. symptoms (EPS), and akathisia.11 Violent behavior. A history of serious violent behavior was reported in: • 5.4% of patients with high positive and low found to affect decision-making capacity, but negative PANSS symptom scores negative symptoms and diminished working • 1.7% of patients with low positive and high memory did.12 negative PANSS symptom scores. Consent. Patients’ capacity to give consent to par- CATIE’S UNIQUE DESIGN ticipate in the study was assessed with the Defining effectiveness. CATIE was designed in MacArthur Competence Assessment Tool for three phases (Figure, page 54). Phase 1—dis- Clinical Research (MacCAT-CR). Psychosis cussed here—was a blinded, controlled compari- severity (PANSS positive symptom scale) was not son of four atypical antipsychotics and per- VOL. 5, NO. 2 / FEBRUARY 2006 53 CP_02.06_CATIE.Final 1/17/06 4:51 PM Page 54 CATIE Figure CATIE schizophrenia trial design Phase 1* Phase 2 Phase 3 Double-blind random Participants who discontinue Participants who discontinue treatment assignments phase 1 choose either the phase 2 choose one of the clozapine or ziprasidone following open-label randomization pathways treatments ▼ Olanzapine Clozapine • Aripiprazole 1,460 patients ▼ (open-label) • Clozapine with ▼ Quetiapine schizophrenia R Olazapine, • Fluphenazine decanoate (could have ▼ quetiapine, • Olanzapine psychiatric R or risperidone ▼ Risperidone or medical • Perphenazine comorbidities and be taking ▼ Ziprasidone • Quetiapine ▼ Ziprasidone other R Olazapine, • Risperidone medications) ▼ quetiapine, • Ziprasidone or risperidone ▼ Perphenazine • 2 of the antipsychotics No one assigned to same above drug as in phase 1 R = randomization * Phase 1A: participants with tardive dyskinesia (N=231) do not get randomized to perphenazine; phase 1B: participants who fail perphenazine will be randomized to an atypical (olanzapine, quetiapine, or risperidone) before eligibility for phase 2. Source: Reference 2. phenazine. Results of phases 2 and 3 have yet to 18-month trial in December 2004, and data analy- be published. The primary effectiveness endpoint, sis began in January 2005. Ziprasidone was added “all-cause discontinuation,” was defined as: to phase 1 after 40% of the sample had been • lack of efficacy (patient was switched to enrolled, and aripiprazole was included as an another drug assigned at random) option in the unblinded phase 3. • lack of tolerability (patient requested a Perphenazine was chosen to represent typical drug change) antipsychotics because it has medium potency • safety problem (investigator initiated a and less risk of EPS than high-potency drugs such switch) as haloperidol and is associated with less weight • patient’s decision for any reason (often gain than low-potency drugs such as thioridazine. dropping out of the study). Dosing. Pharmaceutical manufacturers donated The longer subjects stayed on the first anti- the antipsychotics and were invited to recommend psychotic they received, the more effective that their respective drugs’ starting dosages, dose incre- drug was considered to be. ments, and maximum dosages. Olanzapine’s Medications. Three atypicals—risperidone, olanza- maker requested a higher starting dosage (7.5 pine, and quetiapine—were approved for schizo- mg/d instead of 5.0 mg/d) and a maximum dosage phrenia when the trial began in 1999. Recruitment 50% higher than the FDA-approved range (30 ended in June 2003, the last subject completed the mg/d instead of 20 mg/d). The others recom- 54 Current VOL. 5, NO. 2 / FEBRUARY 2006 p SYCHIATRY CP_02.06_CATIE.FinalREV 1/18/06 2:17 PM Page 55 Current p SYCHIATRY mended the FDA-approved Table 3 dosage ranges or less: All-cause discontinuation rates in the CATIE trial • quetiapine, 200 to 800 mg/d Percent Duration on Dosage Antipsychotic discontinued antipsychotic (months)* (mg/d)* • risperidone, 1.5 to 6 mg/d Olanzapine 64% 9.2 20.1 • ziprasidone, 40 to 160 mg/d Perphenazine 75% 4.6 20.8 • perphenazine, 8 to Quetiapine 82% 4.8 543.4 32 mg/d. The study team accepted Risperidone 74% 5.6 3.9 their recommendations. The medications were Ziprasidone 79% 3.5 112.8 packaged in identical cap- Overall 74% Median 6.0; mean 8.3 sules.
Load more

Recommended publications
  • Standard Operating Procedure Initiation And
    STANDARD OPERATING PROCEDURE Title: Procedure Document Version INITIATION AND PRESCRIBING OF PALIPERIDONE No: Replaced: LONG ACTING INJECTION (PLAI) Clinical N/A 2 SOP 03 Procedure Written By: Procedure Approved By: Approved Review Page Senior Pharmacist Gurj Bhella Date: Date: Deputy Chief Pharmacist Chief Pharmacist 22/05/2018 22/05/2020 1 of 3 Objective To ensure that all prescriptions for paliperidone are initiated by consultants on a named-patient basis and that a record of all patients is kept. Scope All BCPFT consultant teams, Pharmacy Team. Procedure 1. When a patient is identified as being a candidate for paliperidone LAI, the following criteria must be fulfilled: a. The prescribing of a typical antipsychotic depot injection first line has been tried to no effect or has not been tolerated, or is not considered clinically appropriate. b. PLAI to be initiated by Consultants only and be prescribed for its licensed indication only i.e. for maintenance treatment of schizophrenia in adult patients stabilised with risperidone (Oral or LAI) or have responded to it previously. In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, it may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed. Patients may now be switched from oral risperidone as well as risperidone LAI. c. PLAI must be prescribed in line with the treatment guidance for the use of long acting injections contained within NICE guideline CG178 ‘Psychosis and schizophrenia in adults: treatment and management’ issued February 2014. d. Paliperidone LAI must be prescribed once each calendar month i.e.12 times a year.
    [Show full text]
  • Medication Conversion Chart
    Fluphenazine FREQUENCY CONVERSION RATIO ROUTE USUAL DOSE (Range) (Range) OTHER INFORMATION KINETICS Prolixin® PO to IM Oral PO 2.5-20 mg/dy QD - QID NA ↑ dose by 2.5mg/dy Q week. After symptoms controlled, slowly ↓ dose to 1-5mg/dy (dosed QD) Onset: ≤ 1hr 1mg (2-60 mg/dy) Caution for doses > 20mg/dy (↑ risk EPS) Cmax: 0.5hr 2.5mg Elderly: Initial dose = 1 - 2.5mg/dy t½: 14.7-15.3hr 5mg Oral Soln: Dilute in 2oz water, tomato or fruit juice, milk, or uncaffeinated carbonated drinks Duration of Action: 6-8hr 10mg Avoid caffeinated drinks (coffee, cola), tannics (tea), or pectinates (apple juice) 2° possible incompatibilityElimination: Hepatic to inactive metabolites 5mg/ml soln Hemodialysis: Not dialyzable HCl IM 2.5-10 mg/dy Q6-8 hr 1/3-1/2 po dose = IM dose Initial dose (usual): 1.25mg Onset: ≤ 1hr Immediate Caution for doses > 10mg/dy Cmax: 1.5-2hr Release t½: 14.7-15.3hr 2.5mg/ml Duration Action: 6-8hr Elimination: Hepatic to inactive metabolites Hemodialysis: Not dialyzable Decanoate IM 12.5-50mg Q2-3 wks 10mg po = 12.5mg IM CONVERTING FROM PO TO LONG-ACTING DECANOATE: Onset: 24-72hr (4-72hr) Long-Acting SC (12.5-100mg) (1-4 wks) Round to nearest 12.5mg Method 1: 1.25 X po daily dose = equiv decanoate dose; admin Q2-3wks. Cont ½ po daily dose X 1st few mths Cmax: 48-96hr 25mg/ml Method 2: ↑ decanoate dose over 4wks & ↓ po dose over 4-8wks as follows (accelerate taper for sx of EPS): t½: 6.8-9.6dy (single dose) ORAL DECANOATE (Administer Q 2 weeks) 15dy (14-100dy chronic administration) ORAL DOSE (mg/dy) ↓ DOSE OVER (wks) INITIAL DOSE (mg) TARGET DOSE (mg) DOSE OVER (wks) Steady State: 2mth (1.5-3mth) 5 4 6.25 6.25 0 Duration Action: 2wk (1-6wk) Elimination: Hepatic to inactive metabolites 10 4 6.25 12.5 4 Hemodialysis: Not dialyzable 20 8 6.25 12.5 4 30 8 6.25 25 4 40 8 6.25 25 4 Method 3: Admin equivalent decanoate dose Q2-3wks.
    [Show full text]
  • Adjunctive Risperidone Treatment for Antidepressant-Resistant
    Supplementary Online Content Krystal JH, Rosenheck RA, Cramer JA, et al. Adjunctive risperidone treatment for antidepressant- resistant symptoms of chronic military service–related PTSD. JAMA. 2011;306(5):493-502. eTable 1. Follow-up Drugs Started After Randomization eTable 2. Baseline Medications eTable 3. Number of Different Drugs From Each Major Class Each Patient Is Taking at Baseline eTable 4. Baseline Medication Combinations eTable 5. Adverse Events eFigure 1. Product-Limit Survival Estimates With Number of Subjects at Risk eFigure 2. Percentage of Veterans at Each CAPS Severity Level at 24 Weeks, by Treatment This supplementary material has been provided by the authors to give readers additional information about their work. © 2011 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/23/2021 eTable 1. Follow-up Drugs Started After Randomization Placebo Risperidone N= 134 N= 133 Total Patients % Patients % Patients % p-value Drugs started after randomization 46 34.3 59 44.4 105 39.3 0.10 Adrenergic Drugs 4 3.0 5 3.8 9 3.4 0.75 Atenolol 0 0.0 2 1.5 2 0.7 Metoprolol 3 2.2 2 1.5 5 1.9 Propranolol 1 0.7 1 0.8 2 0.7 Opiates 22 16.4 19 14.3 41 15.4 0.73 Codeine 1 0.7 1 0.8 2 0.7 Fentanyl 3 2.2 0 0.0 3 1.1 Hydrocodone (With Or Without 13 9.7 10 7.5 23 8.6 Acetaminophen) Methadone 1 0.7 0 0.0 1 0.4 Morphine 3 2.2 2 1.5 5 1.9 Oxycodone (With Or Without 4 3.0 7 5.3 11 4.1 Acetaminophen) Tramadol 3 2.2 2 1.5 5 1.9 Psycho-Stimulants 0 0.0 2 1.5 2 0.7 0.25 Methylphenidate 0 0.0 2 1.5 2 0.7 Muscle
    [Show full text]
  • PRODUCT INFORMATION Perphenazine Item No
    PRODUCT INFORMATION Perphenazine Item No. 20735 CAS Registry No.: 58-39-9 HO Formal Name: 4-[3-(2-chloro-10H-phenothiazin-10-yl) N propyl]-1-piperazineethanol N Synonyms: NSC 150866, SCH 3940 MF: C21H26ClN3OS FW: 404.0 Purity: ≥98% N Cl UV/Vis.: λmax: 257, 312 nm Supplied as: A crystalline solid Storage: -20°C S Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Perphenazine is supplied as a crystalline solid. A stock solution may be made by dissolving the perphenazine in the solvent of choice, which should be purged with an inert gas. Perphenazine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of perphenazine in these solvents is approximately 5, 20, and 30 mg/ml, respectively. Description 1 Perphenazine is a typical antipsychotic. It binds to dopamine D2, α1A-, α2A-, α2B-, and α2C-adrenergic, M3 muscarinic, and histamine H1 receptors (Kis = 1.4, 10, 1,848, 104.9, 85.2, 810.5 and 8 nM, respectively), as well as the serotonin (5-HT) receptor subtypes 5-HT1A, 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 (Kis = 421, 5.6, 132, 17, and 23 nM, respectively). Perphenazine (1, 5, and 10 mg/kg) enhances morphine-induced analgesia in the tail-flick and hot plate tests in rats.2 It reduces cannibalism in female mice when administered at doses of 2 and 4 mg/kg.3 Formulations containing perphenazine have been used in the treatment of schizophrenia and psychosis. References 1.
    [Show full text]
  • Appendix 13C: Clinical Evidence Study Characteristics Tables
    APPENDIX 13C: CLINICAL EVIDENCE STUDY CHARACTERISTICS TABLES: PHARMACOLOGICAL INTERVENTIONS Abbreviations ............................................................................................................ 3 APPENDIX 13C (I): INCLUDED STUDIES FOR INITIAL TREATMENT WITH ANTIPSYCHOTIC MEDICATION .................................. 4 ARANGO2009 .................................................................................................................................. 4 BERGER2008 .................................................................................................................................... 6 LIEBERMAN2003 ............................................................................................................................ 8 MCEVOY2007 ................................................................................................................................ 10 ROBINSON2006 ............................................................................................................................. 12 SCHOOLER2005 ............................................................................................................................ 14 SIKICH2008 .................................................................................................................................... 16 SWADI2010..................................................................................................................................... 19 VANBRUGGEN2003 ....................................................................................................................
    [Show full text]
  • Datasheet Inhibitors / Agonists / Screening Libraries a DRUG SCREENING EXPERT
    Datasheet Inhibitors / Agonists / Screening Libraries A DRUG SCREENING EXPERT Product Name : Aripiprazole Lauroxil Catalog Number : T14319 CAS Number : 1259305-29-7 Molecular Formula : C36H51Cl2N3O4 Molecular Weight : 660.71 Description: Aripiprazole lauroxil is cleaved by body’s enzyme esterase to N-hydroxymethyl aripiprazole (plus lauric acid) and then to aripiprazole (plus formaldehyde), no toxicity[1]. Aripiprazole lauroxil, an N-acyloxymethyl prodrug of aripiprazole, is a Long-acting injectable (LAI) typical antipsychotic for schizophrenia. Storage: 2 years -80°C in solvent; 3 years -20°C powder; Receptor (IC50) Others In vivo Activity Aripiprazole lauroxil (intravenous administration; 1.87 mg/ml) bioconversion in vivo involves the formation of an intermediate, N- hydroxymethyl aripiprazole. The in vitro data indicates a high bioconversion of aripiprazole lauroxil, thus, the concentration of N- hydroxymethyl aripiprazole observed in the animals dosed with aripiprazole lauroxil is surprisingly high[1]. Reference 1. Jann MW, et al. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.CNS Drugs. 2018 Mar;32(3):241-257. 2. Rohde M, et al. Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug.Results Pharma Sci. 2014 May 2;4:19-25. FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE. Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents.
    [Show full text]
  • Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss
    Supplemental Material can be found at: /content/suppl/2020/12/18/73.1.202.DC1.html 1521-0081/73/1/202–277$35.00 https://doi.org/10.1124/pharmrev.120.000056 PHARMACOLOGICAL REVIEWS Pharmacol Rev 73:202–277, January 2021 Copyright © 2020 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: MICHAEL NADER Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanismss Antonio Inserra, Danilo De Gregorio, and Gabriella Gobbi Neurobiological Psychiatry Unit, Department of Psychiatry, McGill University, Montreal, Quebec, Canada Abstract ...................................................................................205 Significance Statement. ..................................................................205 I. Introduction . ..............................................................................205 A. Review Outline ........................................................................205 B. Psychiatric Disorders and the Need for Novel Pharmacotherapies .......................206 C. Psychedelic Compounds as Novel Therapeutics in Psychiatry: Overview and Comparison with Current Available Treatments . .....................................206 D. Classical or Serotonergic Psychedelics versus Nonclassical Psychedelics: Definition ......208 Downloaded from E. Dissociative Anesthetics................................................................209 F. Empathogens-Entactogens . ............................................................209
    [Show full text]
  • INVEGA SUSTENNA® (Paliperidone Palmitate)
    INVEGA SUSTENNA® INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use (paliperidone palmitate) extended-release injectable suspension, for intramuscular use --------------------------- DOSAGE FORMS AND STRENGTHS --------------------------- HIGHLIGHTS OF PRESCRIBING INFORMATION Extended-release injectable suspension: 39 mg/0.25 mL, 78 mg/0.5 mL, 117 mg/0.75 mL, These highlights do not include all the information needed to use 156 mg/mL, or 234 mg/1.5 mL (3) INVEGA SUSTENNA® safely and effectively. See full prescribing information for INVEGA SUSTENNA®. ----------------------------------- CONTRAINDICATIONS ----------------------------------- INVEGA SUSTENNA® (paliperidone palmitate) extended-release injectable Known hypersensitivity to paliperidone, risperidone, or to any excipients in suspension, for intramuscular use INVEGA SUSTENNA®. (4) Initial U.S. Approval: 2006 -----------------------------WARNINGS AND PRECAUTIONS ----------------------------- WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS • Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with WITH DEMENTIA-RELATED PSYCHOSIS Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse See full prescribing information for complete boxed warning. reactions (e.g. stroke, transient ischemic attack). (5.2) • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of Elderly patients with dementia-related psychosis treated with antipsychotic drug and close monitoring. (5.3) drugs are
    [Show full text]
  • Treatment of Adult Major Depressive Disorder (MDD) Tool
    Section: A B C D E F G Resources References Treatment of Adult Major Depressive Disorder (MDD) Tool This tool is designed to support primary care providers in the treatment of adult patients (≥ 18 years) who have major depressive disorder (MDD). MDD is the most prevalent depressive disorder, and approximately 7% of Canadians meet the diagnostic criteria every year.1,2 The treatment of MDD involves psychotherapy and/or pharmacotherapy. Providers should work with patients to create a treatment plan together using providers’ clinical expertise and keeping in mind the patient’s preferences, as well as the practicality, feasibility, availability and affordability of treatment. TABLE OF CONTENTS pg. 1 Section A: Overview of MDD pathway pg. 6 Section E: Complementary and alternative medicine pg. 2 Section B: Assessing suicidality and managing pg. 7 Section F: Follow-up and monitoring suicide-related behaviour pg. 9 Section G: Special patient populations pg. 3 Section C: Psychotherapy options pg. 10 Resources pg.3 Section D: Pharmacotherapy management SECTION A: Overview of MDD pathway Patient has suspected depression Talking Points It is important to provide your patient with non-judgmental care (e.g. “Being Consider unexpected life events (e.g. death in the family, diagnosed with depression is nothing to be ashamed of, it is very common and change in family status, financial crisis). Consider special many adults are diagnosed with it every year”) patient populations. • Don’t use clinical/psychiatric language (e.g. “mental health,” “psychiatric,” and/or “maladaptive”) unless the patient uses these terms first • Use understandable language for cognitive distortions (e.g.
    [Show full text]
  • Product Data Sheet
    Product data sheet MedKoo Cat#: 326728 Name: Aripiprazole lauroxil CAS#: 1259305-29-7 (lauroxil) Chemical Formula: C36H51Cl2N3O4 Exact Mass: 659.3257 Molecular Weight: 660.721 Product supplied as: Powder Purity (by HPLC): ≥ 98% Shipping conditions Ambient temperature Storage conditions: Powder: -20°C 3 years; 4°C 2 years. In solvent: -80°C 3 months; -20°C 2 weeks. 1. Product description: Aripiprazole lauroxil, aslo known as RDC 3317, is a long-acting injectable atypical antipsychotic. It is an N-acyloxymethyl prodrug of aripiprazole that is administered via intramuscular injection once every four to six weeks for the treatment of schizophrenia. Aripiprazole lauroxil was approved by the U.S. FDA on 5 October 2015. 2. CoA, QC data, SDS, and handling instruction SDS and handling instruction, CoA with copies of QC data (NMR, HPLC and MS analytical spectra) can be downloaded from the product web page under “QC And Documents” section. Note: copies of analytical spectra may not be available if the product is being supplied by MedKoo partners. Whether the product was made by MedKoo or provided by its partners, the quality is 100% guaranteed. 3. Solubility data Solvent Max Conc. mg/mL Max Conc. mM DMSO 8.33 12.61 4. Stock solution preparation table: Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg 1 mM 1.51 mL 7.57 mL 15.13 mL 5 mM 0.30 mL 1.51 mL 3.03 mL 10 mM 0.15 mL 0.76 mL 1.51 mL 50 mM 0.03 mL 0.15 mL 0.30 mL 5.
    [Show full text]
  • Drug Information Sheet
    University Health System PSYCHIATRIC SERVICES Antipsychotics "Depot" Injectable Typical Neuroleptics Fluphenazine Decanoate (Prolixin Decanoate®) Haloperidol Decanoate (Haldol Decanoate®) Course of Treatment: _________________________________________________________________________________ PURPOSE AND GENERAL INFORMATION 1. This medication is used to treat a variety of psychiatric problems such as overactivity, preoccupation with troublesome and recurring thoughts, and unpleasant and unusual experiences such as hearing and seeing things not normally heard nor seen. This medication will reduce or stop these experiences and help you remain outside the hospital. 2. This medication cannot "cure" the illness, but it can take away many of the symptoms or make them milder. It is important to take this medication as directed, even when you begin to feel better. It is necessary to continue taking this medication in order to keep feeling well. 3. Depot medication is an alternative to taking medicine by mouth. An injection is used to deposit medication into muscle tissue and from there the medication is slowly released into your system over a number of weeks. When medication is taken by mouth, it is quickly absorbed through the stomach and intestines; unfortunately, much of it is lost in this digestive process. 4. This medication does not produce euphoria (a high feeling) and is not addictive. BENEFITS Relief of Symptoms 1. Reduction or elimination of voices or visions not heard nor seen by others. 2. Reduction or elimination of frightening or strange beliefs and ideas not shared by others. 3. Decreased tension and agitation with more calm, relaxed feelings. 4. Improved concentration and clearer thinking; better control over thoughts and feelings with less hostile, strange, or aggressive thoughts.
    [Show full text]
  • Optimal Duration of Risperidone Or Olanzapine Adjunctive Therapy to Mood Stabilizer Following Remission of a Manic Episode: a CANMAT Randomized Double-Blind Trial
    Molecular Psychiatry (2016) 21, 1050–1056 OPEN © 2016 Macmillan Publishers Limited All rights reserved 1359-4184/16 www.nature.com/mp ORIGINAL ARTICLE Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial LN Yatham1, S Beaulieu2, A Schaffer3, M Kauer-Sant’Anna4, F Kapczinski4, B Lafer5, V Sharma6, SV Parikh7, A Daigneault8, H Qian9, DJ Bond1, PH Silverstone10, N Walji1, R Milev11, P Baruch12, A da Cunha13, J Quevedo14, R Dias5, M Kunz4, LT Young15, RW Lam1 and H Wong16 Atypical antipsychotic adjunctive therapy to lithium or valproate is effective in treating acute mania. Although continuation of atypical antipsychotic adjunctive therapy after mania remission reduces relapse of mood episodes, the optimal duration is unknown. As many atypical antipsychotics cause weight gain and metabolic syndrome, they should not be continued unless the benefits outweigh the risks. This 52-week double-blind placebo-controlled trial recruited patients with bipolar I disorder (n = 159) who recently remitted from a manic episode during treatment with risperidone or olanzapine adjunctive therapy to lithium or valproate. Patients were randomized to one of three conditions: discontinuation of risperidone or olanzapine and substitution with placebo at (i) entry (‘0-weeks’ group) or (ii) at 24 weeks after entry (‘24-weeks’ group) or (iii) continuation of risperidone or olanzapine for the full duration of the study (‘52-weeks’ group). The primary outcome measure was time to relapse of any mood episode. Compared with the 0-weeks group, the time to any mood episode was significantly longer in the 24-weeks group (hazard ratio (HR) 0.53; 95% confidence interval (CI): 0.33, 0.86) and nearly so in the 52-weeks group (HR: 0.63; 95% CI: 0.39, 1.02).
    [Show full text]